SBIR / HHS / NIH / NCI · Jan 2025
Federal award record showing Velorum Therapeutics Inc. received a Phase II SBIR award totaling $772,293 for VEL-03 IND-enabling development.
Breakthrough medicines unlocking the biology of heme
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Velorum Therapeutics is a South San Francisco biotech developing heme-biology-based medicines, with a lead cancer program aimed at starving tumors by sequestering heme and a pipeline that also includes porphyria and heme-injury applications.
Primary product
VEL-03, a proprietary heme-sequestering therapeutic candidate for oncology (starting with lung cancer) and other solid tumors
Founded
2023
Headquarters
329 Oyster Point Blvd, 3rd Floor, South San Francisco, CA 94080
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Oncology therapeutics / heme biology
Offices
329 Oyster Point Blvd, 3rd Floor, South San Francisco, CA 94080
Open Positions
0 jobs at Velorum Therapeutics
No open positions
Check back later for new openings